undamentalytics Newsletter
Sign in

Lexicon Pharmaceuticals, Inc. (LXRX) stock

Add to watchlist

Add holding +

NASDAQ: LXRX Nasdaq Biotechnology Next results ~November 5, 2026

C Fundamentals grade

Lexicon Pharmaceuticals, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Lexicon Pharmaceuticals, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Lexicon Pharmaceuticals, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders2 buying, 0 selling8 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds80 adding, 66 cuttingOf 32 active managers that changed their stake, 17 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Lexicon Pharmaceuticals files

Where Lexicon Pharmaceuticals stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $41m, down 29.0% on a year earlier, against growth of 123.1% a quarter earlier. Free-cash-flow margin rose to -156.7% from -174.4% a year earlier. Operating margin widened to -131.4% from -202.6%. The diluted share count is up 7.9% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 3 of our 6 financial-health checks.

Our model value for Lexicon Pharmaceuticals is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Lexicon Pharmaceuticals, Inc.'s trailing-twelve-month revenue fell 29.0% year on year, with a free-cash-flow margin of -156.7%. Where it stands out: gross margin of 99.1% ranks 4 of 75 biotechnology companies we cover. Where it lags: change in growth rate of -152.2pp ranks 161 of 172 biotechnology companies we cover.

Current signal Revenue growth decelerating: TTM revenue growth slowed to -29.0% (-152.2pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 71.2 points on a year ago.

Things to watch

  • Revenue shrinking. Revenue fell 29.0% over the last 12 months.
  • Growth slowing. The growth rate is 152.2 points lower than a quarter earlier.
  • Loss-making. Operating margin is -131.4%: costs exceed revenue.
  • Burning cash. Free cash flow was -156.7% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 30.4% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 7.9% in a year.

Latest results: FY2026 Q2

Filed August 6, 2026
Earnings per share
-$0.06 against an average estimate of -$0.05: missed by 24.8%
Revenue
$1m, down 97.6% on a year earlier
Share reaction
+0.8% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Next report
November 5, 2026; average EPS estimate -$0.05

Lexicon Pharmaceuticals' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+1.4%
  • 1 week-1.4%
  • 1 month-19.8%
  • This year+25.2%
  • 1 year+7.4%
  • 5 years-70.6%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$41.5M
Operating margin
-131.4%
Net margin
-147.4%
EPS (TTM, diluted)
$-0.16

Growth

Revenue growth
−29.0%
Change in growth rate
−152.2 pts
Share count change
+7.9%

Cash

Free cash flow (TTM)
-$65M
FCF margin
-156.7%
Stock pay % of revenue
30.4%

Earnings

Last results
August 6, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Lexicon Pharmaceuticals, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Lexicon Pharmaceuticals, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.3%: the 10-year Treasury yield (4.9%) plus a beta of 0.97 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$0.2 ~$0.2–$0.2 Left out: out of range vs price (0.17x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$0.1 ~$0.1–$0.5 Left out: out of range vs price (0.08x)
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Lexicon Pharmaceuticals, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$13.31$13.83$9.88$6.64$4.15$3.42$3.94$1.91$1.53$0.74$1.15$1.44
Market value$1.4bn$1.4bn$1.0bn$703m$485m$379m$574m$317m$338m$237m$418m$563m
+ Net debt (− = net cash)−$97m$55m$190m$170m$213m−$114m−$63m$2m$77m$34m$20m$11m
Enterprise value$1.3bn$1.5bn$1.2bn$872m$697m$265m$511m$319m$415m$270m$437m$574m
Multiples
Price / sales 10.6x18.1x11.3x11.1x1.5x15.8xn/mn/mn/m7.6x8.4x13.6x
Price / earnings ————3.7x———————
Price / free cash flow 7.5x———4.3x———————
EV / EBITDA n/m———4.8x———————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

26 /100

Weak moat

How hard Lexicon Pharmaceuticals's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -39.0% of total assets over 10 years.

  • Pricing power 19 / 20

    Gross margin has been a median 97.8%, moving by 3.2 percentage points (standard deviation) across 8 years.

  • Durability 10 / 20

    Operating margin has been a median -148.8%; its worst year was -31557.6%.

  • Cash conversion 2 / 20

    Free cash flow was positive in 2 of 10 years, at a median -205.9% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 202.3% over five years; stock-based pay has been a median 24.1% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (31 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, before the open. Analysts expect revenue of $4m and EPS of −$0.05 (range −$0.06 to −$0.04) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.17 −19% $37m −25%
Next −$0.19 −15% $17m −55%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +4.8% on 90 days ago. In the last 30 days, 0 analysts raised Lexicon Pharmaceuticals, Inc.'s forecast and 2 cut it.

Consensus EPS forecast Lexicon Pharmaceuticals, Inc., last 90 days
−$0.30 −$0.20 −$0.10 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.16 Current fiscal year, 60 days ago: −$0.17 Current fiscal year, 30 days ago: −$0.17 Current fiscal year, 7 days ago: −$0.17 Current fiscal year, Now: −$0.17 −$0.17 Next fiscal year, 90 days ago: −$0.21 Next fiscal year, 60 days ago: −$0.19 Next fiscal year, 30 days ago: −$0.19 Next fiscal year, 7 days ago: −$0.19 Next fiscal year, Now: −$0.19 −$0.19

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.16−$0.21
60 days ago −$0.17−$0.19
30 days ago −$0.17−$0.19
7 days ago −$0.17−$0.19
Now −$0.17−$0.19

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.05 −$0.06 −24.8%
Mar 2026 −$0.04 $0.00 +100.0%
Dec 2025 −$0.07 −$0.04 +43.6%
Sept 2025 −$0.07 −$0.04 +39.4%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 6, 2026

No numeric guidance in Lexicon Pharmaceuticals, Inc.'s latest earnings release (filed August 6, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

6 analysts, Oct 2026
Buy467%
Hold233%
Sell00%

Monthly trend

  1. Oct 20261326
  2. Sep 20261326
  3. Aug 20261225
  4. Jul 20261225

Counts of recommendations published by analysts covering Lexicon Pharmaceuticals, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
11.3%
of tradable shares
Days to cover
8.55
at average volume
Short interest, 1 month
−7%
to October 15, 2026
Held by institutions
84%
of shares
Held by insiders
1.1%
of shares
Employees
81
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +4.3%

$1.38 on October 31, 2025 to $1.44

ThenNowEffect
Revenue (last 12 months) $58m $41m −29.0%
P/S multiple 8.6x 13.6x +58.7%
Share count 362m 391m −7.3%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
LXRX+15%−52%−20%−52%+55%+25%
Industry peers (median)−36%−57%−17%−28%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
LXRX42%33%50%42%67%64%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
LXRX−63%−67%−71%−82%−71%−46%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 99% from October 10, 2016 to March 3, 2025. Getting back needed a 6555% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.14 – $2.64
From 52-week high
−45.5%
vs 50-day average
−23.1%
vs 200-day average
−23.6%
Volatility (1 year)
74%
Beta vs S&P 500
1.45

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 5 down
typical move ±13.8%
After a week
7 up, 5 down
typical move ±16.2%
After a month
7 up, 5 down
typical move ±11.4%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 +0.8% +0.5% −4.5% −8.6%
May 7, 2026 +25.0% +0.5% +45.6% +17.5%
March 5, 2026 +4.9% −1.9% +5.5% −2.5%
January 29, 2026 −22.7% −0.5% −21.3% +4.0%
November 6, 2025 −9.4% −1.0% +4.3% +0.7%
August 6, 2025 +6.7% +0.7% +5.7% +3.8%
May 13, 2025 −20.9% +0.8% −14.9% +4.5%
March 6, 2025 +14.7% −1.2% +5.9% +23.5%
November 12, 2024 −14.2% −0.3% −30.7% −35.4%
August 1, 2024 −24.4% −3.3% −25.3% −23.1%
May 2, 2024 +5.5% +2.2% +14.5% +6.1%
March 11, 2024 +16.1% +1.0% +16.1% −6.9%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Lexicon Pharmaceuticals, Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Lexicon Pharmaceuticals, Inc.
$0 $20M $40M $60M $80M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $531K Revenue (TTM), FY23 Q4: $1.2M Revenue (TTM), FY24 Q1: $2.3M Revenue (TTM), FY24 Q2: $3.6M Revenue (TTM), FY24 Q3: $5.2M Revenue (TTM), FY24 Q4: $31.1M Revenue (TTM), FY25 Q1: $31.2M Revenue (TTM), FY25 Q2: $58.4M Revenue (TTM), FY25 Q3: $70.9M Revenue (TTM), FY25 Q4: $49.8M Revenue (TTM), FY26 Q1: $69.6M Revenue (TTM), FY26 Q2: $41.5M $41.5M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $531K
FY23 Q4 $1.2M
FY24 Q1 $2.3M
FY24 Q2 $3.6M
FY24 Q3 $5.2M
FY24 Q4 $31.1M
FY25 Q1 $31.2M
FY25 Q2 $58.4M
FY25 Q3 $70.9M
FY25 Q4 $49.8M
FY26 Q1 $69.6M
FY26 Q2 $41.5M
Revenue growth, TTM YoY Lexicon Pharmaceuticals, Inc.
-1000% 0% 1000% 2000% 3000% FY21 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY21 Q3: -98.5% Revenue growth, TTM YoY, FY21 Q4: -98.8% Revenue growth, TTM YoY, FY24 Q1: 1734.1% Revenue growth, TTM YoY, FY24 Q2: 792.4% Revenue growth, TTM YoY, FY24 Q3: 884.7% Revenue growth, TTM YoY, FY24 Q4: 2479.3% Revenue growth, TTM YoY, FY25 Q1: 1250.6% Revenue growth, TTM YoY, FY25 Q2: 1504.8% Revenue growth, TTM YoY, FY25 Q3: 1255.2% Revenue growth, TTM YoY, FY25 Q4: 60.2% Revenue growth, TTM YoY, FY26 Q1: 123.1% Revenue growth, TTM YoY, FY26 Q2: -29.0% -29.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY21 Q3 -98.5%
FY21 Q4 -98.8%
FY24 Q1 1734.1%
FY24 Q2 792.4%
FY24 Q3 884.7%
FY24 Q4 2479.3%
FY25 Q1 1250.6%
FY25 Q2 1504.8%
FY25 Q3 1255.2%
FY25 Q4 60.2%
FY26 Q1 123.1%
FY26 Q2 -29.0%
Operating margin (TTM) Lexicon Pharmaceuticals, Inc.
-30000% -20000% -10000% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -29245.0% Operating margin (TTM), FY23 Q4: -14253.1% Operating margin (TTM), FY24 Q1: -8045.9% Operating margin (TTM), FY24 Q2: -5412.1% Operating margin (TTM), FY24 Q3: -4037.4% Operating margin (TTM), FY24 Q4: -634.2% Operating margin (TTM), FY25 Q1: -568.6% Operating margin (TTM), FY25 Q2: -202.6% Operating margin (TTM), FY25 Q3: -94.4% Operating margin (TTM), FY25 Q4: -98.2% Operating margin (TTM), FY26 Q1: -34.8% Operating margin (TTM), FY26 Q2: -131.4% -131.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -29245.0%
FY23 Q4 -14253.1%
FY24 Q1 -8045.9%
FY24 Q2 -5412.1%
FY24 Q3 -4037.4%
FY24 Q4 -634.2%
FY25 Q1 -568.6%
FY25 Q2 -202.6%
FY25 Q3 -94.4%
FY25 Q4 -98.2%
FY26 Q1 -34.8%
FY26 Q2 -131.4%
FCF margin (TTM) Lexicon Pharmaceuticals, Inc.
-30000% -20000% -10000% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -25354.8% FCF margin (TTM), FY23 Q4: -13474.4% FCF margin (TTM), FY24 Q1: -8032.7% FCF margin (TTM), FY24 Q2: -5387.8% FCF margin (TTM), FY24 Q3: -3985.4% FCF margin (TTM), FY24 Q4: -578.5% FCF margin (TTM), FY25 Q1: -536.4% FCF margin (TTM), FY25 Q2: -174.4% FCF margin (TTM), FY25 Q3: -101.8% FCF margin (TTM), FY25 Q4: -136.2% FCF margin (TTM), FY26 Q1: -55.7% FCF margin (TTM), FY26 Q2: -156.7% -156.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -25354.8%
FY23 Q4 -13474.4%
FY24 Q1 -8032.7%
FY24 Q2 -5387.8%
FY24 Q3 -3985.4%
FY24 Q4 -578.5%
FY25 Q1 -536.4%
FY25 Q2 -174.4%
FY25 Q3 -101.8%
FY25 Q4 -136.2%
FY26 Q1 -55.7%
FY26 Q2 -156.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 11 5 2 1 2 23 130 79 92 63 322 24 0 0 1 31 50 41
Gross profit — — — — — — — 79 90 61 319 22 0 0 1 30 50 41
EBITDA −84 −90 −109 −104 −100 −98 2 −125 −127 −100 145 −45 −87 −100 −171 −197 −48 −54
Operating income −90 −96 −114 −108 −102 −100 1 −127 −131 −103 141 −48 −87 −101 −172 −197 −49 −55
Net income −83 −102 −116 −110 −104 −100 −5 −131 −123 −121 130 −59 −88 −102 −177 −200 −50 −61
Diluted EPS −$0.57 −$2.38 −$2.38 −$1.61 −$1.42 −$1.31 −$0.05 −$1.27 −$1.17 −$1.14 $1.16 −$0.53 −$0.60 −$0.62 −$0.80 −$0.63 −$0.14 −$0.16
Growth (year on year)
Revenue — −54.1% −62.3% −41.1% +104.0% +928.5% +468.9% −39.0% +15.7% −31.1% +409.5% −92.5% −98.8% −53.4% +766.2% +>999% +60.2% −29.0%
EBITDA — — — — — — — — — — — −130.9% — — — — — —
Operating income — — — — — — — — — — — −133.8% — — — — — —
Net income — — — — — — — — — — — −145.0% — — — — — —
Diluted EPS — — — — — — — — — — — −145.7% — — — — — —
Margins
Gross margin — — — — — — — 100.0% 97.9% 96.1% 99.0% 92.0% 100.0% 100.0% 92.9% 98.0% 99.4% 99.1%
EBITDA margin −783.1% <−999% <−999% <−999% <−999% −430.7% 1.7% −157.9% −138.8% −157.6% 45.1% −187.0% <−999% <−999% <−999% −632.5% −97.0% −130.3%
Operating margin −840.7% <−999% <−999% <−999% <−999% −439.2% 1.1% −160.5% −142.5% −163.4% 43.9% −199.2% <−999% <−999% <−999% −634.2% −98.2% −131.4%
Net margin −773.6% <−999% <−999% <−999% <−999% −438.8% −3.6% −165.8% −134.1% −190.7% 40.4% −244.1% <−999% <−999% <−999% −644.8% −101.1% −147.4%
Free-cash-flow margin −835.4% <−999% <−999% <−999% <−999% −331.2% 141.4% −221.9% −202.4% −235.3% 35.3% −596.2% <−999% <−999% <−999% −578.5% −136.2% −156.7%
Cash flow
Cash from operations −89 −82 −88 −94 −91 −76 185 −176 −185 −149 114 −143 −87 −89 −162 −179 −68 −65
Capital spending 0 1 1 0 2 0 1 0 0 0 0 0 1 1 0 1 0 0
Free cash flow −89 −84 −89 −95 −93 −76 184 −176 −186 −149 114 −143 −88 −90 −162 −180 −68 −65
Stock-based pay 5 5 6 6 7 7 7 7 9 12 14 13 11 12 14 13 13 13
Free cash flow after stock pay −95 −89 −95 −101 −100 −83 177 −183 −195 −160 100 −156 −99 −102 −177 −193 −80 −78
Balance sheet
Cash 101 47 186 30 37 137 203 47 62 80 36 126 64 46 22 67 34 41
Total debt 0 28 25 23 22 108 106 101 252 250 249 12 1 49 100 100 54 51
Net debt (negative = net cash) −101 −19 −161 −7 −16 −30 −97 55 190 170 213 −114 −63 2 77 34 20 11
Diluted shares — 43m 49m 70m 73m 76m 104m 104m 105m 106m 117m 111m 146m 166m 221m 320m 363m 391m
Returned to shareholders
Buybacks 0 0 0 0 1 1 0 1 2 1 1 1 3 1 1 2 — —
Total returned 0 0 0 0 1 1 0 1 2 1 1 1 3 1 1 2 — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

3 of 6 checks passed · June 30, 2026
What it owns · $250m
Short-term assets $197mLonger-term assets $53m
What it owes, and who funded it · $250m
Short-term liabilities $15mLonger-term liabilities $61mShareholders' equity $175m
  • Short-term assets cover short-term liabilities $197m of assets due within a year against $15m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $197m short-term assets against $61m of longer-dated liabilities.
  • More cash than debt $41m of cash against $51m of debt.
  • Debt below 40% of shareholders' equity Debt is 29% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 0% to 29% over five years.
  • A year's operating cash flow covers at least 20% of debt −$65m of operating cash flow against $51m of debt.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Lexicon Pharmaceuticals, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+7.9%
year over year
R&D spending
145.3%
of revenue
Sales & admin spending
85.2%
of revenue
Days sales outstanding
14 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated LXRX CUE STRO ZYME NBTX FHTX Median
Revenue, last 12 months $41m $38m $46m $37m $37m $37m $56m
Revenue growth, last 12 months −29.0% 354.4% −56.3% −69.8% 678.4% 52.0% 12.6%
Revenue growth, 3-year average 366.7% 176.2% −7.0% −56.4% — 19.1% 13.7%
Revenue growth, latest quarter −97.6% 166.7% −84.6% −90.6% — 112.7% 10.2%
Operating margin −131.4% −262.0% −319.6% −419.0% −33.2% −198.0% −189.4%
Operating margin, 3-year average <−999% −439.8% −192.8% −235.1% — −284.9% −363.5%
Net margin −147.4% −435.8% −395.2% −404.0% −73.5% −175.8% −169.8%
Cash from operations / revenue −156.7% −132.9% −317.7% −321.4% −102.5% −229.3% −168.0%
Free-cash-flow margin −156.7% −133.2% −330.9% −324.7% −104.2% −229.4% −162.4%
Free-cash-flow margin, 3-year average <−999% −313.4% −208.2% −168.9% — −306.5% −310.0%
Stock pay / revenue 30.4% 69.1% 14.8% 89.6% 10.9% 27.0% 20.0%
Change in share count 7.9% 74.2% 20.6% −2.2% 1.2% 5.9% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth -29.0% 12.6% 130 of 172
Change in growth rate Growth -152.2pp -0.1pp 161 of 172
Gross margin Profitability 99.1% 82.4% 4 of 75
Operating margin Profitability -131.4% -189.4% 81 of 175
Net margin Profitability -147.4% -157.3% 87 of 180
Free-cash-flow margin Cash generation -156.7% -145.4% 89 of 176
Stock pay as % of revenue Cash generation 30.4% 19.2% 103 of 179
Long-term debt as % of assets Balance sheet 20.6% 20.6% 40 of 78
Change in share count Balance sheet 7.9% 7.9% 79 of 156
Days sales outstanding Balance sheet 14 days 75 days 9 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Licenses $45M 90.6% ▲ 80.0%
Products $4.6M 9.4% ▼ 22.6%

From Lexicon Pharmaceuticals, Inc.'s 10-K filed March 5, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$875M
Institutions reporting
148
Shares held vs prior quarter
▲ 12.7%
Positions opened / closed
44 / 30

Top buyers and sellers, Q2 2026: 80 institutions bought and 66 sold ; the biggest buyer was Artal Group S.A (+20.4M shares) and the biggest seller Millennium Management LLC (−3.8M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Artal Group S.A. $420M 175.2M 48.0% ▲ 13.2%
FMR LLC $124M 51.8M 14.2% ▲ 14.9%
Siren, L.L.C. $106M 44.3M 12.2% 0.0%
Sessa Capital Im, L.P. $45.5M 19.0M 5.2% ▲ 5.8%
Blackrock, Inc. $41.6M 17.3M 4.8% ▲ 422.2%
Vanguard Capital Management LLC $23.8M 9.9M 2.7% ▲ 4.0%
Point72 Asset Management, L.P. $19.8M 8.3M 2.3% ▲ 5.6%
Geode Capital Management, LLC $15M 6.2M 1.7% ▲ 97.0%
State Street Corp $11.8M 4.9M 1.3% ▲ 410.1%
Vanguard Portfolio Management LLC $5.7M 2.4M 0.6% ▲ 331.3%
Northern Trust Corp $4.7M 2.0M 0.5% ▲ 298.0%
Charles Schwab Investment Management Inc $4.7M 2.0M 0.5% ▲ 49.2%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Lexicon Pharmaceuticals, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $2.7M 8 trades by 2 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $2.7M net buying
Insider Date Trade Shares Price Value
Debbane Raymond Director February 25, 2026 Buy 2,000 $1.49 $2,980
Debbane Raymond Director February 23, 2026 Buy 100,000 $1.47 $147,000
Debbane Raymond Director February 20, 2026 Buy 100,000 $1.48 $148,000
Debbane Raymond Director February 19, 2026 Buy 50,000 $1.44 $72,000
Debbane Raymond Director February 18, 2026 Buy 133,688 $1.32 $176,468
Debbane Raymond Director February 17, 2026 Buy 76,857 $1.31 $100,683
Debbane Raymond Director February 13, 2026 Buy 57,952 $1.31 $75,917
Artal Group S.A. Director February 2, 2026 Buy 1,538,462 $1.30 $2M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around October 29, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 7, 2026
  • March 5, 2026
  • January 29, 2026
  • November 6, 2025
  • August 6, 2025

Recent SEC filings

Data status

When each part of this page on Lexicon Pharmaceuticals, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Lexicon Pharmaceuticals, Inc. in brief

What does Lexicon Pharmaceuticals, Inc. do?
Lexicon Pharmaceuticals, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Lexicon Pharmaceuticals, Inc.'s stock ticker?
Lexicon Pharmaceuticals, Inc. trades under the ticker LXRX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Lexicon Pharmaceuticals, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Lexicon Pharmaceuticals, Inc. reported revenue of $41.5M, 29.0% lower than a year earlier, according to its SEC filings.
What is Lexicon Pharmaceuticals, Inc.'s free cash flow?
Lexicon Pharmaceuticals, Inc.'s free-cash-flow margin is -156.7% of revenue over the trailing twelve months, ranking 89 of the 176 biotechnology companies we cover.
Who are Lexicon Pharmaceuticals, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Artal Group S.A., FMR LLC and Siren, L.L.C. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Lexicon Pharmaceuticals, Inc.'s market cap?
On November 2, 2026, Lexicon Pharmaceuticals, Inc.'s market capitalisation was about $563M and net debt of $10.5M. Market figures come from third-party market data and may be delayed.
How much debt does Lexicon Pharmaceuticals, Inc. have?
Lexicon Pharmaceuticals, Inc.'s debt-to-equity ratio is 29.5%, from its latest balance sheet (0.0% five years earlier). The financial health section below sets out its other solvency checks.
Who are Lexicon Pharmaceuticals, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Lexicon Pharmaceuticals, Inc. are Cue Biopharma, Inc., Sutro Biopharma, Inc., Zymeworks Inc., Nanobiotix S.a. and Foghorn Therapeutics Inc. The side-by-side comparison below sets their revenue, margins and growth against Lexicon Pharmaceuticals, Inc.'s.
Are insiders buying or selling Lexicon Pharmaceuticals, Inc. stock?
Over the last 12 months, Lexicon Pharmaceuticals, Inc.'s directors and officers reported 8 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Lexicon Pharmaceuticals, Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Lexicon Pharmaceuticals, Inc. announces its own schedule.